Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase I clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella—two major causes of illness and death among children in sub-Saharan Africa.
Vaccine shows promise against typhoid and invasive Salmonella in first human trial
